<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01979367</url>
  </required_header>
  <id_info>
    <org_study_id>DTSC030113</org_study_id>
    <nct_id>NCT01979367</nct_id>
  </id_info>
  <brief_title>Physician Clinical Trial Policy (CTP) Neurological Ischemia Lower Extremity Pain and Swelling</brief_title>
  <acronym>DTSC</acronym>
  <official_title>To Evaluate the Efficacy Treatment of Lower Extremity Pathologies Derived From Neurological Ischemia Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Association of Sensory Electrodiagnostic Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Association of Sensory Electrodiagnostic Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Physician Clinical Trial Policy (CTP) to evaluate the efficacy treatment of lower extremity&#xD;
      pathologies derived from neurological ischemia disorders using the combination of&#xD;
      Monochromatic Infrared Photo Energy (MIRE) and Transcutaneous Electrical Nerve Stimulation&#xD;
      (TENS) therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although there are a number of pain disorders, associated with back, or lower extremity pain&#xD;
      and swelling, the American Association of Sensory Electrodiagnostic Medicine (AASEM/ DTSC)&#xD;
      study programs will accumulate received data following a protocol of treatment performed for&#xD;
      the purpose of eliminating pain, reducing swelling, and accelerating recovery periods as well&#xD;
      as to record the success or failure and/or improvement of the malfunctioning body part.&#xD;
&#xD;
        -  Condition: Neuropathic Pain, Tingling or Numbness derived from neurological Ischemia&#xD;
&#xD;
        -  Intervention: Treatments of Monochromatic Infrared Photo Energy (MIRE) in combination&#xD;
           with Electronic Signal Treatment (TENS) therapy&#xD;
&#xD;
        -  Study Type: Interventional&#xD;
&#xD;
        -  Study Design:&#xD;
&#xD;
             1. Allocation: Non-Randomized&#xD;
&#xD;
             2. Endpoint Classification: Efficacy Study&#xD;
&#xD;
             3. Intervention Model: Single Group Assignment&#xD;
&#xD;
             4. Masking: Open Label&#xD;
&#xD;
             5. Primary Purpose: Scientific record of treatment success or failure&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome: Scientific record of treatment success or failure</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lower Extremity Swelling Acute</condition>
  <arm_group>
    <arm_group_label>Anodyne</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate the efficacy treatment of lower extremity pathologies from neurological ischemia disorders using the Monochromatic Infrared Photo Energy (MIRE)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anodyne</intervention_name>
    <description>Subjects will be treated with MIRE therapy using the Anodyne® device within 72 hours of previous treatments, and in accordance with the Anodyne® package insert indications for use 30 to 45 minutes professional units on power setting of 8,. In addition, patients will undergo TENS therapy with the use of either the Avazzia® Pro Sport or TENS 3000 (for no less than 30 mins, both on label) in accordance with the indications for use of each TENS device, for a minimum of 15 minutes at the subjective site for pain and each vertebrae nerve base, when impairment is confirmed with the objective Small Pain Fiber (SPF) Nerve Conduction Study (NCS) test performed.</description>
    <arm_group_label>Anodyne</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In the investigator's judgment, a high probability of 5 year survival and compliance&#xD;
             with the study visit schedule.&#xD;
&#xD;
        Ability to comprehend and sign an informed consent document prior to study enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other excluding factors that, according to the investigator's judgment, would&#xD;
             preclude enrollment in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Boyer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>American Association of Sensory Electrodiagnostic Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danielle Sanders, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Association of Sensory Electrodiagnostic Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chad Pfefer, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>American Association of Sensory Electrodiagnostic Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Doyce Cartrett, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Association of Sensory Electrodiagnostic Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald S Covington, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Association of Sensory Electrodiagnostic Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Curequest Clinical LLC</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erie Medical and Rehab</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silsbee Family Medicine PA</name>
      <address>
        <city>Silsbee</city>
        <state>Texas</state>
        <zip>77656</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>November 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2013</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

